Biogen selects new CEO: former Sanofi head Chris Viehbacher
Biogen’s months-long search for a new CEO landed on the choice of former Sanofi CEO Chris Viehbacher, who was previously ousted from his top spot at the French company.
Viehbacher will be stepping into Biogen at a tumultuous moment as its first Alzheimer’s drug Aduhelm failed at launch without payer coverage, but its next up-and-coming amyloid-targeted drug lecanemab shows promise in recently released results that could amount to a full approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.